Sign in
CompletedPhase 2

A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps

Key facts

Who runs it
Sanofi
Where
Atlanta, Bellaire, Boise, Boston, Dallas, La Jolla, McKinney, Norfolk, Ogden, Roseville, San Antonio, San Diego, Tampa, and Tulsa, United StatesSee the 14 sitesAlso in 5 other countries, 15 sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
79 people enrolled
Started
17 Jul 2024
Ended
23 Apr 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • lunsekimig
  • placebo
Record updated
28 April 2026

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • A minimum bilateral nasal polyp score of 5 out of a maximum score of 8 for both nostrils (with at least a score of 2 for each nostril) despite use of intranasal corticosteroid treatment for at least 2 months prior to screening; Ongoing symptoms for at least 2 months prior to screening, including:
  • Nasal congestion, blockage, or obstruction with moderate or severe symptom severity at screening (Score 2 or 3 on NC Score) and a weekly average severity score of at least 1 (range 0 to 3) at randomization (NC Score: 0=no symptoms, 1=mild, 2=moderate, and 3=severe)
  • At least 1 of the following 2 symptoms: (1) partial loss of smell (hyposmia) or total loss of smell (anosmia); (2) anterior and/or posterior rhinorrhea

Who cannot take part

  • Patient who has received any therapies such as for example systemic corticosteroids, anti-IgE therapy, monoclonal antibody and some others in the specified timeframe(s) prior to the screening visit
  • Patients who have undergone any nasal/sinus surgery within 6 months before screening or for whom NPS cannot be determined accurately on endoscopy due to anatomic changes to the nasal cavity from past nasal/sinus surgery
  • Patients with conditions/concomitant diseases making them non evaluable for the primary efficacy endpoint
  • Signs or a CT scan suggestive of Allergic fungal rhinosinusitis
  • Active/chronic helminthic infection
  • History of human immunodeficiency virus (HIV) infection or positive HIV screen (Anti-HIV- and HIV-2 antibodies) at screening visit
  • Patients with positive or indeterminate hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C antibody at screening visit NOTE: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
  • Participants are excluded from the study if any of the following criteria apply:

Where in United States

Also in 5 other countries, 15 sites

  • Emory University Hospital Midtown- Site Number : 8400012Atlanta, United States
  • McGovern Medical School - UT Physicians Dermatology - Bellaire Station- Site Number : 8400017Bellaire, United States
  • The Allergy Group - Asthma & Allergy Boise- Site Number : 8400002Boise, United States
  • Harvard Medical School - Brigham and Women's Hospital Site Number : 8400016Boston, United States
  • Gary Gross Pharmaceutical Research & Consulting, Inc. Site Number : 8400004Dallas, United States
  • La Jolla, CaliforniaHospital not named in the registry
  • Berkson Medical - McKinney- Site Number : 8400014McKinney, United States
  • Eastern Virginia Medical School (EVMS) Medical Group- Site Number : 8400008Norfolk, United States
  • Advanced Research Institute - Odgen- Site Number : 8400022Ogden, United States
  • Sacramento Ear Nose & Throat - Roseville- Site Number : 8400003Roseville, United States
  • San Antonio, TexasHospital not named in the registry
  • Senta Clinic- Site Number : 8400025San Diego, United States
  • James A Haley Veterans' Hospital- Site Number : 8400015Tampa, United States
  • Essential Medical Research- Site Number : 8400020Tulsa, United States

About the trial

What the trial wants to find out

This is a parallel, Phase 2, 2-arm, multicenter, randomized, double-blind, placebo-controlled, proof-of-concept study for treatment of CRSwNP.

Read full original descriptionShow less

The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with subcutaneous lunsekimig in adult participants (aged 18 to 70 years, inclusive) with CRSwNP who are inadequately controlled on intranasal corticosteroid treatment. Participants with and without co-morbid asthma will be included in the study, and lung function will be assessed in both groups.

The study duration will be up to approximately 40 weeks per participant, including 4 weeks of screening run-in period, 24 weeks of intervention period, and 12 weeks of follow-up.

The 2 groups in the trial

  • Arm 1Placebo, for comparison

    Participant will receive placebo subcutaneous (SC) every 4 weeks and intranasal mometasone furoate nasal spray (MFNS) for 24 weeks.

    Treatment: placebo

  • Arm 2Treatment being tested

    Participant will receive lunsekimig subcutaneous (SC) every 4 weeks and intranasal mometasone furoate nasal spray (MFNS) for 24 weeks.

    Treatment: lunsekimig

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Record updated
28 April 2026